The Joys and Concerns Behind BeiGene's First Profit

2025 is a critical year for $BEONE MEDICINES (06160.HK)$ is undoubtedly a landmark year for the company. According to its Q4 and full-year 2025 financial report, this leading Chinese innovative pharmaceutical company achieved its first annual profit more than a decade after its establishment. The adjusted net profit reached 918 million US dollars, marking a qualitative leap from a net loss of 54.92 million US dollars in the same period last year.

Looking at the full-year data, $BeOne Medicines Ltd. (688235.SH)$ In 2025, total operating revenue reached 5.343 billion USD, a year-on-year increase of 40.23%. Product revenue increased by 39.75% year-on-year to 5.282 billion USD. The adjusted gross margin was approximately 87.81%, higher than the previous year's 85.54%. Adjusted R&D expenses rose by 11.25%, and adjusted sales expenses increased by 12.47% year-on-year. Adjusted operating profit reached 1.1 billion USD, compared with only 45 million USD in the same period last year, achieving a turnaround from losses to profits. Adjusted net profit reached 918 million USD, compared with a loss of 55 million USD in the previous year.

However, an in-depth analysis of this report card reveals not only exciting breakthroughs but also hidden concerns that cannot be ignored behind the impressive figures.

Hidden Concerns Emerge: Sequential Slowdown and Fixed Costs

In Q4 2025, $BeiGene (ONC.US)$ Total revenue reached 1.498 billion USD, a year-on-year increase of 32.84%, mainly driven by the strong performance of the core product, Brukinsa (Zanubrutinib). Data shows that global sales of Brukinsa in Q4 reached 1.1 billion USD, a year-on-year increase of 38%.

A significant improvement in profitability was the highlight of the Q4 year-on-year data. We noticed that the adjusted gross margin for Q4 increased from 87.36% in the same period last year to 90.69%, possibly reflecting the continuous improvement in operational efficiency brought about by the scaled production of Brukinsa. As a result, the adjusted operating profit margin reached 22.99%, far higher than 6.97% in the same period last year. The adjusted net profit reached 225 million USD, a nearly 13-fold increase from 16 million USD in the same period last year.

However, comparing Q4 performance with Q3 paints a less optimistic picture: several key metrics showed mediocre sequential performance or even declines.

Data shows that product revenue in Q4 increased by only 5.84% sequentially. More notably, costs rose significantly: adjusted R&D expenses increased by 22.18% sequentially, and adjusted sales and administrative expenses increased by 8.51% sequentially. The rapid growth in costs may have eroded profit margins, leading to a 25.91% sequential decrease in adjusted net profit for the quarter to 225 million USD.

These sequential data indicate that although Beigene maintained strong growth on a year-on-year basis, the rapid increase in R&D and sales expenses in the short term may not have brought about a corresponding proportion of revenue growth, which has raised some market concerns about the company's cost control capabilities to a certain extent.

Brukinsa: Contributing 74% of Total Revenue

For the full year 2025, BeiGene's product revenue grew by 39.75% year-over-year to reach USD 5.282 billion, with Brukinsa standing out as a key performer. Its annual sales reached USD 3.9 billion, reflecting a 49% year-over-year growth and accounting for an impressive 74% of total revenue.

Regionally, Brukinsa's revenue is heavily concentrated in the U.S. market. Data shows that the U.S. contributed USD 2.8 billion for the year, a 45% year-over-year increase, representing 72% of Brukinsa's total annual revenue. According to its A-share earnings report, Europe saw the fastest growth at 66.4% year-over-year, while China's sales amounted to RMB 2.472 billion (approximately USD 3.6 billion), up 33.1% year-over-year.

This revenue structure highlights two major dependency risks for BeiGene: an over-reliance on a single product (Brukinsa contributing 74%) and an over-reliance on a single market (the U.S. accounting for 72% of Brukinsa’s revenue). While this dual-concentration model has driven rapid growth, it also exposes the company to significant geopolitical and market risks.

Tislelizumab: Second Growth Engine Shows Weak Quarter-on-Quarter Performance

As BeiGene's second-largest revenue source, Tislelizumab generated global sales of USD 737 million in 2025, marking a 19% year-over-year increase. Notably, Tislelizumab contributed USD 182 million in the fourth quarter, a decline from over USD 190 million in the previous two quarters.

Although Tislelizumab has been approved in more than 50 markets worldwide, its growth momentum remains relatively moderate, contrasting sharply with Brukinsa’s rapid expansion. Amid intensifying competition in the PD-1 market, Tislelizumab’s role as a secondary growth engine still appears insufficient, failing to effectively alleviate the revenue reliance on Brukinsa.

2026 Outlook: Growth Guidance and Market Reaction

BeiGene has provided clear guidance for its 2026 performance, forecasting total revenue between USD 6.2 billion and USD 6.4 billion, implying a year-over-year growth of approximately 16%-20%. GAAP operating profit is projected at USD 700 million to USD 800 million, compared to USD 447 million in 2025, while non-GAAP operating profit is expected to be USD 1.4 billion to USD 1.5 billion, suggesting a year-over-year increase of 53%-63%.

Based on the guidance, the company anticipates that gross margin in 2026 will remain at the high end of the 80% range, despite already achieving 87.49% in 2025, leaving limited room for further improvement. This outlook has heightened market scrutiny regarding the quality and sustainability of the company’s profitability.

Following the earnings announcement, Beigene's A-shares, H-shares, and US shares were all sold off, possibly reflecting market dissatisfaction with its outlook.

Core Risk Analysis: Heavy Dependence on Brukinsa

Brukinsa accounted for 74% of Beigene's total revenue, a highly concentrated level in the pharmaceutical industry. Although Brukinsa, as the BTK inhibitor approved for the widest range of indications globally, has established itself as a leader in hematological oncology, the business model that relies heavily on a single product carries significant inherent risks.

From a product lifecycle perspective, Brukinsa is in the late stage of rapid growth, and its growth rate will gradually slow down. The 49% year-on-year growth projected for 2025 already shows a decline compared to previous years when it doubled annually. With increasing competition among BTK inhibitors and the emergence of next-generation therapies, maintaining high growth rates for Brukinsa will become increasingly challenging.

More critically, Brukinsa's revenue is highly concentrated in the US market (accounting for 72%). Against the backdrop of complex geopolitical relations between China and the US, this market concentration exposes the company to significant policy risks. Any tariffs, access restrictions, or changes in pricing policies targeting Chinese pharmaceutical companies could significantly impact Beigene's revenue.

Additionally, ongoing negotiations over healthcare insurance and drug pricing reforms in the US market may adversely affect Brukinsa's price and market share in the future. The company needs to accelerate its expansion into the European, Japanese, and other markets to reduce its heavy reliance on the US market.

Key to Future Growth: Can the Product Pipeline Break the Single Dependency?

In response to the aforementioned risks, Beigene's future hinges on whether it can cultivate new growth engines through its robust R&D pipeline, gradually reducing its heavy dependence on Brukinsa. Based on the current pipeline layout, the company is making active efforts in this direction.

In the field of hematological oncology, the BCL2 inhibitor BGB-11417 (Sonrotoclax) is the company’s most promising next core product. This drug received the world's first marketing approval in China in January 2026 for treating adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) and adult patients with R/R CLL/SLL who have previously received at least one systemic treatment including a BTK inhibitor.

BGB-11417 has been granted priority review status by the US FDA and is expected to receive regulatory approval from the FDA for R/R MCL in the first half of 2026. Additionally, an application for marketing authorization for BGB-11417 for treating adult patients with R/R MCL has been submitted in the EU. The combination therapy regimen of BGB-11417 with a BTK inhibitor has entered a critical clinical phase, potentially forming a combinatory strategy in the field of hematological oncology.

In addition, the BTK CDAC candidate drug BGB-16673 is designed to address BTK inhibitor resistance, with Phase I CLL data presented at the 2025 ASH Annual Meeting showing positive results. A potential accelerated approval application is expected to be submitted in the second half of 2026.

Solid tumors represent a core focus for Beigene's pipeline expansion, which currently includes 26 drug candidates covering small molecule inhibitors, ADCs, and bispecific/trispecific antibodies, targeting high-incidence cancers such as lung cancer, breast cancer, liver cancer, and gastrointestinal cancer.

Among them, BGB-B2033 (a GPC3×41BB bispecific antibody) has received FDA Fast Track designation for the treatment of adult patients with hepatocellular carcinoma who experience disease progression during or after systemic therapy. The company expects to initiate a potentially pivotal Phase II trial for this drug in the second half of 2026.

The CDK4 inhibitor BGB-43395 also shows promise, with a Phase III trial for first-line treatment of HR+/HER2- metastatic breast cancer expected to commence in the first half of 2026. Progress in these solid tumor pipelines will lay the foundation for the company’s expansion from hematological malignancies into the solid tumor space.

Diversified Technology Platform Layout

Beigene’s diversified approach to technological platforms deserves attention. The company covers various cutting-edge technologies, including small molecule inhibitors, monoclonal antibodies, ADCs, bispecific/trispecific antibodies, and protein degraders (CDAC), with a particularly leading position in the field of protein degraders.

In next-generation cell therapies, the company’s first allogeneic T-cell therapy derived from induced pluripotent stem cells (iPSC) is set to begin its first-in-human trial in 2026, a technology that could significantly reduce the cost of cell therapies.

Evaluation of Commercial Prospects for Next-Generation Pipelines

Overall, Beigene's product pipeline demonstrates several key characteristics:

Key highlight one: An initial combination strategy in hematological malignancies has been established. Centered around BeiGene's core product, BRUKINSA, alongside BeiGene-Da (a BCL2 inhibitor) and BGB-16673 (BTK CDAC), the company has formed a comprehensive product matrix addressing different targets and resistance mechanisms within the hematological malignancy field.

Key highlight two: differentiated pipeline for solid tumors. The 26 drug candidates cover multiple technological approaches, primarily targeting major indications such as lung cancer, breast cancer, and liver cancer, with some drugs already in the late stages of clinical trials.

Key highlight three: focus on unmet clinical needs. The pipeline specifically addresses drug resistance issues, such as BGB-16673 addressing resistance to BTK inhibitors and BG-68501 tackling resistance to CDK4/6 inhibitors, providing later-line treatment options for patients.

Nevertheless, most of these drug candidates are still in the early stages of clinical trials, and there is a long way to go before commercialization. In the short term, BeiGene will continue to heavily rely on the contribution of Brukinsa. Based on the 2026 revenue guidance, the company expects total revenue growth to be between 16% and 20%, lower than the 40% year-over-year increase in 2025 revenue, reflecting growth pressure due to a high base.

Conclusion

The milestone significance of BeiGene's 2025 performance is undeniable – achieving its first full-year profit, with core product Brukinsa sales exceeding $3.9 billion, establishing global leadership in the BTK inhibitor market, and turning free cash flow positive for the year. These achievements mark that the company has initially developed self-sustaining capabilities, transitioning from a research-driven biotech company to a commercially mature biopharmaceutical enterprise.

However, the path to transformation is not without challenges. Weak quarter-on-quarter growth in Q4 and the 2026 guidance revealing a slowdown in growth highlight the core challenges it faces: how to maintain growth momentum on a high base and how to transition from Brukinsa's single-driver model to multi-product synergistic growth.

From the perspective of R&D pipeline layout, the company has prepared sufficient resources for the next phase of growth: Beilad may become the next key commercial product, and the 26 drug candidates in the solid tumor field lay the foundation for long-term development. However, most of these pipeline products are still in the early stages of clinical trials, and the commercialization process will take time. In the next 2-3 years, BeiGene will still heavily depend on Brukinsa's performance.

Author: Wu Yan

47K Views